Stockscreener 앱 받기
12.72
3.94%
-0.505
Bioage Labs Inc 주식(BIOA)의 최신 뉴스
Can BioAge Labs Inc. stock deliver sustainable ROEQuarterly Earnings Review & Maximum Profit Growth - bollywoodhelpline.com
BIOA INVESTORS: Kirby McInerney LLP Reminds BioAge Labs, Inc. Investors of Important Deadline and Encourages Investors to Contact the Firm - TMX Newsfile
BioAge Labs (NASDAQ:BIOA) Sets New 52-Week HighStill a Buy? - MarketBeat
Cash per share of BioAge Labs, Inc. – FWB:Y7G - TradingView — Track All Markets
BioAge Labs, Inc.(NasdaqGS: BIOA) added to NASDAQ Biotechnology Index - marketscreener.com
BioAge Labs announces positive phase 1 trial results - MSN
BioAge Labs (BIOA) Price Target Increased by 24.14% to 12.24 - Nasdaq
Is BioAge Labs Inc. stock dividend yield sustainableJuly 2025 Catalysts & Real-Time Volume Trigger Notifications - Улправда
Can BioAge Labs Inc. stock continue upward trendMarket Activity Summary & Verified Momentum Stock Ideas - Улправда
Why BioAge Labs Inc. (Y7G) stock is listed among top recommendationsQuarterly Market Review & Risk Controlled Daily Trade Plans - DonanımHaber
What makes BioAge Labs Inc. stock attractive to growth fundsJuly 2025 Levels & Precise Swing Trade Alerts - DonanımHaber
Can BioAge Labs Inc. stock withstand economic slowdown2025 Technical Overview & Technical Confirmation Alerts - DonanımHaber
How analysts rate BioAge Labs Inc. stock today2025 Volume Leaders & High Accuracy Investment Signals - DonanımHaber
Bioage Labs Earnings Notes - Trefis
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Globe and Mail
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole - The Motley Fool
Bioage Labs Stock Rockets 52% With 8-Day Winning Streak - Trefis
Paul Rubin Sells 18,000 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
BioAge Labs CMO Paul D. Rubin Sells 18,000 Shares - TradingView — Track All Markets
[Form 4] BioAge Labs, Inc. Insider Trading Activity - Stock Titan
Officer Rubin Files To Sell 18,000 Of BioAge Labs Inc [BIOA] - TradingView — Track All Markets
Morgan Stanley Upgrades BioAge Labs (BIOA) - Nasdaq
BioAge Labs (BIOA) Competitors and Alternatives 2025 - MarketBeat
Volume Recap: How BioAge Labs Inc stock reacts to Fed rate cutsFed Meeting & Technical Pattern Recognition Alerts - BỘ NỘI VỤ
Paul Rubin Sells 68,897 Shares of BioAge Labs (NASDAQ:BIOA) Stock - MarketBeat
BioAge Labs (NASDAQ:BIOA) Rating Increased to Hold at Wall Street Zen - MarketBeat
BioAge Labs CMO Paul D. Rubin Sells All Common Stock Holdings - TradingView
Officer Rubin Sells 68,897 ($701.9K) Of BioAge Labs Inc [BIOA] - TradingView
BioAge Labs stock rating upgraded by Morgan Stanley on promising BGE-102 data - Investing.com South Africa
How BioAge Labs Inc. stock reacts to Fed rate cutsShort Setup & Fast Gain Stock Trading Tips - Newser
BioAge’s NLRP3 inhibitor shows positive Phase 1 data in clinical trial - Investing.com Nigeria
Is BioAge Labs Inc. stock a safe haven assetQuarterly Earnings Summary & Safe Entry Zone Identification - Newser
Why BioAge Labs Inc. stock remains undervaluedCEO Change & Smart Money Movement Alerts - Newser
How BioAge Labs Inc. (Y7G) stock stacks up against competitorsInsider Selling & Daily Chart Pattern Signal Reports - Newser
Positive Developments and Promising Trials Bolster Buy Rating for BioAge Labs - TipRanks
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $15 - 富途牛牛
Officer Rubin Files To Sell 68,897 Of BioAge Labs Inc [BIOA] - TradingView
Will BioAge Labs Inc. (Y7G) stock outperform global peersCEO Change & Safe Capital Investment Plans - Newser
Merger Talk: Is BioAge Labs Inc stock a safe haven assetPortfolio Growth Summary & Weekly Watchlist of Top Performers - BỘ NỘI VỤ
BioAge Labs BGE-102 Phase 1 Trial Shows Potential in Targeting Inflammation in Central Nervous System, Peripheral Tissues - marketscreener.com
BioAge Reports Positive Interim Phase 1 Data For BGE-102; Shares Rise - Nasdaq
BioAge Labs Announces Positive Phase 1 Trial Results - TipRanks
BioAge Announces Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor - markets.businessinsider.com
BioAge Labs, Inc. Announces Positive Interim Phase 1 Data for BGE-102 - TradingView — Track All Markets
1.43%
1.81%
자본화:
|
볼륨(24시간):